

## Sero-Detection of Cytomegalovirus and Rubella Virus IgG Antibodies Among Sudanese Pregnant Women in Khartoum State-Sudan

Ola S. Abdul Jaleel, Sara A.Bakhet, Mahmmoud S.Saleh, Mohammed S.Mohammed, Ibrahim T.Ibrahim, Mohamed I. Garbi, and Ali M.Badri\*

Department of Microbiology, Faculty of Medical Laboratory Sciences, International University of Africa. P.O. Box 2469 Khartoum, Sudan

\***Corresponding Author:** Ali M.Badri, Department of Microbiology, Faculty of Medical Laboratory Sciences, International University of Africa. P.O. Box 2469 Khartoum, Sudan, E-mail: [ali.almhasi@gmail.com](mailto:ali.almhasi@gmail.com)

**Received:** 11 April 2017; **Accepted:** 17 April 2017; **Published:** 20 April 2017

### Abstract

**Background:** Cytomegalovirus and Rubella virus are the most common causes of congenital infections, which increase morbidity and mortality at birth and one of the common causes of abortion in developing countries.

**Methodology:** Plasma samples obtained from 87 pregnant womens, the samples were obtained from Omdurman Friendship Hospital 53(61%), AL-Saudi Specialized Hospital 21(25%) and Ultra lab Diagnostic Centre 13(14%).all samples were examined for presence of *CMV* and *Rubella* virus IgG antibodies by using an ELISA test.

**Results:** The result showed that out of 87 blood samples investigated, 64(73.6%) were positive for *CMV*, while the reslt 23(26.4%) were negative and 85(97.7%) were positive for *rubella*, while the reslt 2(2.3%) were negative, where was 62(71.2%) samples had both *CMV* and *Rubella* virus IgG antibodies, 25(28.8%) had either *CMV* or *Rubella* virus IgG antibodies and there was no sample negative for both *CMV* and *Rubella* virus IgG antibodies.

**Conclusion:** The present study observed the high prevalence rate of *CMV* and *rubella virus* IgG antibodies among pregnant women in Khartoum State. The level of infections is higher in pregnant women without history of miscarriage than those aborted women.

**Keywords:** Cytomegalovirus; Rubella Virus; Pregnant Women; IgG Antibody; Sero-Detection

## **1. Introduction**

Congenital CMV infection is one of the TORCH infections (toxoplasmosis, rubella, CMV, and HSV), which carry a risk of significant symptomatic disease and developmental defects in newborns [1]. Human cytomegalovirus (HCMV) belongs to the  $\beta$ -herpesvirus subfamily, and although most healthy individuals remain asymptomatic subsequent to infection, the pathogen is a major contributor to birth defects and to life-threatening disease in immunocompromised patients [2-4]. As with all viruses, HCMV depends on the host cell to provide macromolecular building blocks for virion production, and throughout the course of its evolution, HCMV has adapted to manipulate numerous fundamental cellular processes, including RNA accumulation [5], translation [6], metabolism [7-8], secretory pathways [9], and the cell cycle [10]. Cytomegalovirus infection during pregnancy is a major cause of congenital infection worldwide with an incidence of 0.2 – 2.2% of live births. Up to 15% of such children have newborns following intrauterine CMV infection [11]. Infection in the newborn can be acquired through close contact (via contaminated blood, urine, and secretions), vertically through Trans placental transmission, and postnatal through breast milk [12].

Rubella virus (RuV) is a small enveloped single-stranded RNA virus and the sole member of the Rubivirus genus. Rubivirus and alphaviruses together comprise the Togaviridae [8]. While alphaviruses are generally transmitted by mosquito vectors, RuV spreads by airborne transmission between humans [13]. The only known host [9]. RuV causes a mild childhood disease commonly referred to as German measles [8-10]. Rubella (initially known as German measles) is associated with an 80% risk of usually multiple congenital abnormalities if acquired in the first 12 weeks of pregnancy [14], especially the first 8-10 weeks, and leads to fetal growth problems or still birth [15]. The virus initially replicates in the nasopharyngeal mucosa and local lymph nodes, and in pregnancy infects the placenta and developing fetus.

## **2. Materials and Methods**

### **2.1 Study design and duration**

A descriptive Cross-sectional study was conducted to detect Human Cytomegalovirus and Rubella virus IgG Antibodies among pregnant women attending Omdurman Friendship Hospital, Al-Saudi Maternity Hospital and Ultra Lab Diagnostic Centre, Khartoum, Sudan. During the period from May to June 2016.

### **2.2 Collection and preparation of samples**

A peripheral blood specimen was collected from each pregnant woman into EDTA-containing vacutainer tubes, centrifuged at 3000 RPM for 5 minutes and the obtained plasma was stored at -20°C until used.

### **2.3 Immunoassay for HCMV and Rubella virus IgG antibodies detection**

Plasma samples were examined for anti HCMV and Rubella virus IgG antibodies by an indirect Enzyme-linked Immunosorbent Assay (ELISA) kit (foresight, Acon laboratories, Inc., 10125Mesa Rim Road, San Diego, CA92121, and USA).

## 2.4 Data Analysis

Statistical analysis was done by using Statistical Package for Social Science program (SPSS- version 16).

## 3. Results

A total of eighty seven blood samples (n=87) were collected from pregnant women in Khartoum State. All specimens were examined for the presence of *CMV* and *Rubella* virus IgG antibodies using an ELISA kits.

Out of 87 blood samples investigated, 85(97.7%) and 64(73.6%) were reactive for anti-*CMV* and anti-*Rubella* IgG antibodies, respectively. Of particular interest, 62(71.2%) samples were reactive for both anti-*CMV* and anti-*Rubella* IgG antibodies, whereas there was no sample showed non reactive result for neither anti-*CMV* nor anti-*Rubella* virus IgG antibodies (Table 1).

Result	<i>CMV</i> IgG antibodies		<i>Rubella</i> IgG antibodies		<i>CMV</i> and <i>Rubella</i> IgG antibodies	
	No.	percentage	No.	percentage	No.	Percentage
Positive	64	73.6%	85	97.7%	62	71.2%
Negative	23	26.4%	2	2.3%	25	28.8%
Total	87	100%	87	100%	87	100%

**Table 1:** Prevalence of *CMV* and *Rubella* IgG antibodies among pregnant women

Out of 38 women with history of abortion 31(81.6%) and 37(97.4%) were reactive for anti-*CMV* and anti-*Rubella* virus IgG antibodies, respectively, with P-value (0.882). Moreover out of 49 women without history of abortion 32(65.3%) and 47(95.9%) were reactive for anti-*CMV* and anti-*Rubella* virus IgG antibodies, respectively, with P-value (0.106) (Table 2).

Result		<i>CMV</i> IgG antibodies		<i>Rubella</i> IgG antibodies	
		No.	percentage	No.	Percentage
Abortion (n=38)	Positive	31	81.6%	37	97.4%
	Negative	7	18.4%	1	2.6%
No abortion (n=49)	Positive	32	65.3%	47	95.9%
	Negative	17	34.7%	2	4.1%

**Table 2:** distribution of *CMV* and *Rubella* virus IgG antibodies according to history of abortion

## 4. Discussion

Human cytomegalovirus and Rubella virus are two of the vertically transmitted infections that lead to congenital abnormalities and pregnancy problems. Studies showed that women who are exposed to *cytomegalovirus* and/or *Rubella virus* for the first time during pregnancy may have a higher risk of miscarriage. These infections can lead to

important complications on pregnancy for maternal and fetal health [16,17]. The present study aimed for detection of anti-*CMV* and anti-*Rubella virus* IgG antibodies among pregnant women in Khartoum State.

A total of 87 blood samples investigated, 67(73.6%) and 85(97.7%) were positive for anti-*CMV* and anti-*Rubella virus* IgG antibodies, respectively. Our *CMV* result (73.6%) was similar to that obtained in western Sudan [18] who reported that 72.2% of pregnant women were anti-*CMV*-IgG antibodies reactive, but higher than result obtained in Mexico, (65.6%) by Luis *et al.* [19] and less than those obtained in Nigeria (91.1%) by Hamid *et al.* [20], in Palestine (96.6%) by Tahani *et al.* [21] and in China (98.7%) by Lingqing *et al.* [22]. These differences might be attributed to endemic variations of these countries with *CMV* infections and different health policies enrolled in these countries. Of particular interest, the highest frequencies of reactive anti-*CMV* IgG antibodies were observed among the first trimester of pregnancy and those without history of miscarriage. However, no significant difference ( $P > 0.05$ ) was observed among the three trimesters of pregnancy. While *Rubella virus* results (97.7%) were higher than that obtained in Nigeria and Sudan 70% and 65.3%, respectively [18,23], and in line with the result obtained in Mozambique is almost 100% [24,25]. A number of studies reveal variable results of the seroprevalence of rubella over different continents; 54.1% in Nigerian [26], 76% in Sri Lanka [27], 77.5% in Russian [28] and 93% in Eritrea [29]. These differences may be due to endemicity variations of these countries with rubella infections and recent introduction of *Rubella* vaccine alone or in combination as MMR vaccines in national immunization schedule.

In the present study, the higher (54%) incidence of seropositivity for *rubella virus* IgG antibody was observed in pregnant women without history of miscarriage than that of the normal pregnancy (43.8%) outcomes group, suggested that rubella could be a cause of repeated pregnancy wastage in those women. Similar evidence was seen in Punjab, India that higher (73.2%) incidence was seen in the adverse pregnancy outcome group than the normal (69.5%) obstetric outcome group [30].

Our finding detected that the highest seropositivity of rubella virus was reported in those pregnant women within the third trimester (55.2%) of gestation than others. However, no significant difference ( $P > 0.05$ ) was observed among the three pregnancy trimesters.

## 5. Conclusion

According to our results we conclude that there are high prevalence rate *CMV* and rubella virus IgG antibodies among pregnant women in Khartoum State. The level of infections is higher in those pregnant women without history of miscarriage than those aborted women and statistical analysis shows that there is no significant association between *CMV* and rubella virus infections and abortion.

From this study, we observed that the high prevalence rate of *CMV* and rubella virus infections were found in those women in the third trimester of gestation and those within the age group  $\geq 25$  year-old. The present study also concludes that there is a high rate of mix infections by *CMV* and Rubella virus among pregnant women.

## References

1. Ljungman P, Griffiths P, and Paya C. Definitions of *cytomegalovirus* infection and disease in transplant recipients. *Clin Infect Dis* 34 (2002): 1094-1097.
2. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. *Rev Med Virol* 17 (2007): 355-363.
3. Ross SA, Boppana SB. Congenital cytomegalovirus infection: Outcome and diagnosis. *Semin Pediatr Infect Dis* 16 (2005): 44-49.
4. Gerna G, Baldanti F, Revello MG. Pathogenesis of human cytomegalovirus infection and cellular targets. *Hum Immunol* 65 (2004): 381-386.
5. Yurochko AD. Human cytomegalovirus modulation of signal transduction. *Curr Top Microbiol Immunol* 325 (2008): 205-220.
6. McKinney C. Global reprogramming of the cellular translational landscape facilitates cytomegalovirus replication. *Cell Reports* 6 (2014): 9-17.
7. Yu Y, Clippinger AJ, Alwine JC. Viral effects on metabolism: Changes in glucose and glutamine utilization during human cytomegalovirus infection. *Trends Microbiol* 19 (2011): 360-367.
8. Hobman TC (2013). Rubella virus,. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), *Fields virology*, 6th ed, vol 1. p 687-711. Lippincott Williams & Wilkins, Philadelphia, PA.
9. Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. *Clin Microbiol Rev* 13 (2000):571-587.
10. Frey TK. Molecular biology of rubella virus. *Adv Virus Res* 44 (1994): 69-160.
11. Adler SP. Screening for Cytomegalovirus during Pregnancy. *Infectious Diseases in Obstetrics and Gynecology* 9 (2011): 100-115.
12. Bhide A. Managing primary CMV infection in pregnancy. *BJOG* 115 (2008): 805-807.
13. Alzeidan RA, Wahabi HA, Fayed AA, Esmail SA, Amer YS. Postpartum rubella vaccination for sero-negative women (Protocol). *Cochrane Database of Systematic Reviews* (2013).
14. Best JM. Rubella. *Seminars in Fetal & Neonatal Medicine* 12 (2007): 182-92.
15. World Health Organization. Rubella vaccines: WHO position Weekly Epidemiological Record No 29 86 (2011): 301-16. 33.
16. Best JM, Banatvala JE. Rubella. In: *Principles and Practice of Clinical Virology*. Eds. Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD), Fifth Edition, John Wiley and Sons, Ltd., West Sussex, England (2004): 427-457.

17. Griffiths PD. Cytomegalovirus (In: Principles and Practice of Clinical Virology. Eds. Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD), Fifth Edition, John Wiley and Sons, Ltd., West Sussex, England (2004): 85-122.
18. Hamdan Z, Ismail E, Nasser M and Ishag A. Seroprevalence of cytomegalovirus and rubella among pregnant women in western Sudan. *Virology* 8 (2011): 217-223.
19. Luis FS, Cosme AE, Jesus HT, Sandra MC, Sergio EM, et al. Seroepidemiology of *cytomegalovirus* infection in pregnant women in Durango City, Mexico. *BMC Infect Dis* 14 (2014):1471-2334.
20. Hamid KM, Onoja AB, Tofa UA and Garba KN. Seroprevalence of cytomegalovirus among pregnant women attending Murtala Mohammed Specialist Hospital Kano, Nigeria. *Afr Health Sci* 14 (2014): 125-130.
21. Tahani N, Ayda Q, Niveen Sh, Areej AR, Eman AZ, et al. Seroprevalence of *Cytomegalovirus* among pregnant women and hospitalized children in Palestine. *BMC Infect Dis* 13 (2013): 528-534.
22. Lingqing H, Shu Z, Jie C, Biyun X, Hua Z, et al. Cytomegalovirus Seroprevalence in Pregnant Women and Association with Adverse Pregnancy/Neonatal Outcomes in Jiangsu Province, China. *PLoS One* 9 (2014): 100–117.
23. Onyenekwe CC, Kehinde-Agbeyangi TA, Ofor US, Arinola OG. Prevalence of rubella-IgG antibody in women of childbearing age in Lagos, Nigeria. *West African Journal of Medicine* 19 (2000):23-26.
24. Barreto J, Sacramento I, Robertson SE et al. Antenatal rubella serosurvey in Maputo, Mozambique. *Trop Med Into Health* 11 (2006): 559-564.
25. Lawn JE, Reef S, Baffoe-Bonnie B, Adadevoh S, Caul EO, et al. Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana. *Am J Public Health* 10 (2000): 1555-1561.
26. Bukbuk DN, El nafty AU, Obed JY. Prevalence of rubella-specific IgG antibody in non-immunized pregnant women in Maiduguri, North Eastern Nigeria. *Cent Eur J Public Health* 10 (2002): 21-23.
27. Palhawadan AP, Wickremasingha AR, Perera J. Seroprevalence of rubella antibodies among pregnant females in Sri Lanka. *Southeast. Asian J Trop Med Public Health* 34 (2003): 398-404.
28. Odland JO, Sergejeva IV, Ivaneev MD, Jensen IP, Stray-Pedersen B. Seropositivity of cytomegalovirus, parvovirus and rubella in pregnant women and recurrent aborters in Leningrad County, Russia. *Acta Obstet Gynecol Scand* 80 (2001): 1025-1029.
29. Tolfvenstamt, Enbomm, Ghebrenh, Rudenu, Lindea, et al. Seroprevalence of viral childhood infections in Eritrea. *J Clin Virol* 16 (2000): 49-54.

30. Singla N, Jindal N, Aggarwal A. The seroepidemiology of rubella in Amritsar (Punjab). *Indian Journal of Medical Microbiology* 22 (2004): 61-63.



This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC-BY\) license 4.0](https://creativecommons.org/licenses/by/4.0/)